Carl Zeiss Meditec Presents New Laser System

Friday, 03. April 2009 15:01
Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------




Next generation of VisuMax with shorter treatment times and expanded
application spectrum

JENA - 3rd April 2009.
During the Congress of the American Society of Cataract and
Refractive Surgery (ASCRS) Carl Zeiss Meditec is introducing the next
generation of its VisuMax® femtosecond laser.

Through an increase in the pulse repetition rate, the new system
enhances the precision of the therapy, shortens treatment times and
further improves patient comfort.

In addition, VisuMax can now be used for an additional therapeutic
procedure: corneal transplantation (keratoplasty)*. This opens up a
new clinical application of the system as a therapy laser and expands
its possible field of use outside the context of refractive surgery.

"With the development of the new VisuMax, we have fulfilled the
pledge we have made to doctors to further expand the major potential
of femtosecond technology and place this at their disposal in an
innovative system for ophthalmology in a very short time," Dr.
Michael Kaschke, President and CEO of Carl Zeiss Meditec, explained.

"The major advantage of the 500 kHz upgrade is that it allows for
shorter treatment times with increased laser spot density," said John
Dishler, MD, of Dishler Laser Institute in Greenwood Village, CO.
"Clinically, this produces two significant benefits. First, the
higher repetition rate had reduced the critical phase of the
procedure, the actual laser emission time, even further. Thus the
patient is only required to remain still for a short amount of time.
Secondly, the higher spot density results in even more precise tissue
separation."

With about 120,000 procedures a year around the globe, keratoplasty
is the most frequently performed organ transplantation. The use of
femtosecond laser technology allows precise definition of the
incision form and depth, therefore permitting less invasive surgical
techniques.

* Penetrating keratoplasty is not currently available with the
VisuMax Femtosecond Laser in the US. This new indication is the
subject of a pending 510(k), and will require additional or modified
software that is not currently available for sale in the US.

Contact for the press:
Eva Sesselmann
Director Corporate Communications
Carl Zeiss Meditec AG
Göschwitzer Strasse 51-52
07745 Jena
Germany
Phone: +49 (0) 3641/ 220-331
Fax: +49 (0) 3641/ 220-112
Email: press@meditec.zeiss.com
Patrick Kofler
Director Investor Relations
Carl Zeiss Meditec AG
Göschwitzer Strasse 51-52
07745 Jena
Germany
Phone: +49 (0) 3641/ 220-106
Fax: +49 (0) 3641/ 220-117
Email: investors@meditec.zeiss.com



Brief profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on
TecDAX of the German stock exchange, is one of the world's leading
medical technology companies.
The Company supplies innovative technologies and application-oriented
solutions which enable doctors to improve the quality of life of
their patients. The Company offers complete solutions, including
implants and consumables, to diagnose and treat ophthalmic diseases.
In the field of Neuro/ENT surgery the Company provides innovative
visualization solutions. Carl Zeiss Meditec's medical technology
portfolio is rounded off by promising future technologies such as
intraoperative radiotherapy.
The Company's around 2,100 employees generated revenue of about EUR
600 million in fiscal year 2007/08 (ended Sept. 30). The headquarters
of Carl Zeiss Meditec are located in Jena, Germany. In addition to
other subsidiaries in Germany, the Company is represented by over 50
percent of its employees at sites in the USA, Japan, Spain and
France.
Thirty-five percent of Carl Zeiss Meditec's shares are in free float.
The remaining 65 percent are held by Carl Zeiss AG, one of the
world's leading groups engaged in the optical and opto-electronics
industry. The five independently run business segments of Carl Zeiss
AG operate in the future-oriented markets "Medical and Research
Solutions", "Industrial Solutions" and "Lifestyle Products". Carl
Zeiss AG is headquartered in Oberkochen, Germany. During fiscal year
2007/08 (ended Sept. 30) the company generated revenues of about EUR
2.7 billion. Carl Zeiss has around 13,000 employees in more than 30
countries, including more than 8,000 in Germany.

For further information please visit our website at:
www.meditec.zeiss.com



--- End of Message ---

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany

WKN:
531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share,
TecDAX;
Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Stuttgart,
Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in
Frankfurter Wertpapierbörse;
Related Links: Carl Zeiss Meditec AG
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.